Vaccine News and Research

Latest Vaccine News and Research

Media outlets examine efforts to develop malaria vaccines

Scientists have identified a group of proteins they say could form the basis of a malaria vaccine, Australia's ABC News reports. "However, they say more laboratory work and clinical trials need to be done, with a vaccine at least 10 years away," the news service reports (Macey, 1/19).

20 Jan 2010

Fraunhofer USA CMB receives $60,000 gift from ProTecs to complete vaccine manufacturing plant

The Fraunhofer USA Center for Molecular Biotechnology, a not-for-profit, 501 (c3) research organization, announced today that it has received a $60,000 gift from ProTecs, Inc., to complete its new, state of-the-art vaccine manufacturing plant in Newark, Delaware.

20 Jan 2010

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in combination with cetuximab (Erbitux®) in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

20 Jan 2010

Global health care errors, fraud costs $260b annually, report finds

A report released Monday finds $260 billion - or 5.59 percent of annual global health spending - is lost annually to health care errors and fraud, Reuters reports. For the study, the European Healthcare Fraud and Corruption Network (EHFCN) and the Center for Counter Fraud Services (CCFS) at Britain's Portsmouth University, "reviewed 69 exercises in 33 organizations in six countries to measure healthcare fraud and error losses," the news service reports.

20 Jan 2010

WHO, CDC issue H1N1 updates

Though H1N1 (swine flu) activity worldwide has slowed, the potential of a new wave of infections in the northern hemisphere in late winter or early spring remains viable, Keiji Fukuda, the WHO's top flu expert, said Monday at the start of the WHO's weeklong executive board meeting, Reuters reports.

19 Jan 2010

Scarab Genomics launches White Glove IS Detection Kit

Scarab Genomics has now launched the White Glove IS Detection Kit to test for the presence of transposable Insertion Sequence (IS) elements in a DNA of interest. Numerous IS elements are naturally present in the genomes of E. coli strains commonly used for protein and plasmid production, but are not present in the Scarab Genomics Clean Genome® strains.

19 Jan 2010

Access to clean water remains an issue for victims and Haiti earthquake volunteers

Six days after the magnitude 7.0 earthquake rocked Haiti the health and sanitation situation is still less than optimal in the makeshift camps. "Access to shelter, sanitation, water, food and medical care remains extremely limited," announced Riccardo Conti on a bulletin yesterday from the International Committee of the Red Cross (ICRC's).

19 Jan 2010

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell vaccines targeting house dust mite and cat allergies. With the start of these studies, and the ongoing trial of Circassia's ragweed allergy (hay fever) T-cell vaccine, the company now has three clinical development programmes in phase II.

19 Jan 2010

CSafe and AcuTemp Thermal Systems offer temperature controlled containers for the Haitian relief effort

AcuTemp Thermal Systems, www.acutemp.com, a manufacturer of active and passive containers for transporting temperature sensitive pharmaceutical and bio-medical products; and CSafe, LLC, www.csafellc.com, a provider of active container solutions for the temperature sensitive airfreight market, are offering relief agencies their temperature controlled containers for use in shipping and storing blood, vaccines and other critical temperature sensitive medical supplies for the Haitian relief effort.

19 Jan 2010

New findings support the development of vaccine against malaria

Walter and Eliza Hall Institute researchers have uncovered a group of proteins that could form the basis of an effective vaccine against malaria.

19 Jan 2010

New book on harnessing science and innovation to tackle challenges in poor countries

Science and Innovation for Development demonstrates how science and innovation can be harnessed to tackle today's biggest challenges in poor countries, including climate change, HIV/AIDS and illiteracy. Case studies are described, including the use of tissue culture to develop disease-resistant bananas in Kenya; the use of nanotechnology to develop cheaper and faster kits for diagnosing infectious diseases and the use of organic material to power a multi-purpose stove that can also function as a refrigerator and generator.

18 Jan 2010

PATH MVI announces collaboration in development of malaria TBV

The PATH Malaria Vaccine Initiative (MVI) today announced a new collaboration to initiate development toward a vaccine that may eventually help eliminate and eradicate malaria. This collaboration with the Johns Hopkins Bloomberg School of Public Health (JHSPH) and the Sabin Vaccine Institute (Sabin) marks MVI's first investment in transmission-blocking vaccines (TBVs). This vaccine approach aims to stop the malaria parasite from developing in the mosquito, effectively blocking transmission of malaria from mosquitoes to humans. Malaria kills nearly 900,000 people per year, most of them children younger than age five.

18 Jan 2010

Health personalities: Nelson, Landrieu, Melancon, Regina Benjamin

...

18 Jan 2010

Margaret A. Hamburg thanks America's health care professionals on H1N1 vaccine safety

FDA Commissioner Margaret A. Hamburg today sent a letter to America's health care professionals thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on safety monitoring of the 2009 H1N1 vaccines.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

AVIR Green Hills Biotechnology, the innovative biotech company based in Vienna, has started the New Year by embarking on the first clinical phase II study for the seasonal vaccine deltaFLU. The study will be carried out at the Medical University of Vienna. With this step, AVIR Green Hills has set yet another important milestone in the development of effective and modern influenza vaccines.

18 Jan 2010

Study raises concerns about drug-resistant HIV

The emergence of drug-resistant strains of HIV could one day threaten efforts to control the global HIV pandemic, according to a study published online Thursday in the journal Science, HealthDay News/U.S. News & World Report reports. The researchers based their findings on "a mathematical model that tracks the transmission of multiple strains of HIV" in San Francisco, the news service writes (1/14).

18 Jan 2010

WHO official rejects claims agency overhyped threat of H1N1

Keiji Fukuda, the special adviser to the WHO director general on pandemic influenza, on Thursday dismissed allegations that the agency exaggerated the threat of the H1N1 (swine flu) pandemic and has been influenced by the pharmaceutical industry, the Washington Post reports.

18 Jan 2010

Early immune response needed for 'hit-and-hide' cancer viruses

Retroviruses such as HIV and HTLV-1 don't hit-and-run, they hit-and-hide. They slip into host cells and insert their own DNA into the cell's DNA, and from this refuge they establish an infection that lasts a lifetime.

14 Jan 2010

Vaccine News and Research

Latest Vaccine News and Research

Media outlets examine efforts to develop malaria vaccines

Fraunhofer USA CMB receives $60,000 gift from ProTecs to complete vaccine manufacturing plant

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Global health care errors, fraud costs $260b annually, report finds

WHO, CDC issue H1N1 updates

Scarab Genomics launches White Glove IS Detection Kit

Access to clean water remains an issue for victims and Haiti earthquake volunteers

Circassia commences Phase II trials of its T-cell vaccines against house dust mite and cat allergies

CSafe and AcuTemp Thermal Systems offer temperature controlled containers for the Haitian relief effort

New findings support the development of vaccine against malaria

New book on harnessing science and innovation to tackle challenges in poor countries

PATH MVI announces collaboration in development of malaria TBV

Health personalities: Nelson, Landrieu, Melancon, Regina Benjamin

Margaret A. Hamburg thanks America's health care professionals on H1N1 vaccine safety

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

New findings may yield novel therapies for chronic neurodegenerative diseases

AVIR Green Hills Biotechnology commences deltaFLU Phase II study

Study raises concerns about drug-resistant HIV

WHO official rejects claims agency overhyped threat of H1N1

Early immune response needed for 'hit-and-hide' cancer viruses

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Vaccine News and Research

Latest Vaccine News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in